North America Associated Press
UCB Announces Breakthrough Data on KYGEVVI Therapy for Rare Genetic Disorder TK2d.1
UCB announces publication of data demonstrating positive impact of KYGEVVI therapy in patients with Thymidine Kinase 2 Deficiency (TK2d), showing improved survival and functional outcomes.
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI in Patients with Thymidine Kinase 2 Deficiency (TK2d). The data shows that KYGEVVI therapy improved survival and functional outcomes in people with TK2d, marking a significant milestone for the treatment of this rare genetic disorder.
Brief written with AI from reporting by Associated Press. All rights to the original story belong to the publisher.